TrianglePUBLICATIONS · 8478661
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 1993 Apr
- First author
- Atkins MB
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Atkins MB
- type
- Author
- name
- Sparano J
- type
- Author
- name
- Fisher RI
- type
- Author
- name
- Weiss GR
- type
- Author
- name
- Margolin KA
- type
- Author
- name
- Fink KI
- type
- Author
- name
- Rubinstein L
- type
- Author
- name
- Louie A
- type
- Author
- name
- Mier JW
- type
- Author
- name
- Gucalp R
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Atkins MB
- type
- Author
- name
- Sparano J
- type
- Author
- name
- Fisher RI
- type
- Author
- name
- Weiss GR
- type
- Author
- name
- Margolin KA
- type
- Author
- name
- Fink KI
- type
- Author
- name
- Rubinstein L
- type
- Author
- name
- Louie A
- type
- Author
- name
- Mier JW
- type
- Author
- name
- Gucalp R
- type
- Author
- bibliography ids
- nci-bib-a0a90eb0a51fbd20e5c4d9bf
- book metadata
- content sha256
- 1be79525b1b14996ef7f046dea6a75a8f621d2a77d6a5ee83fce731a3e7acc74
- document type
- citation
- dois
- 10.1200/JCO.1993.11.4.661
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:8478661
- immutable id
- pubmed:8478661@1be79525b1b14996ef7f046dea6a75a8f621d2a77d6a5ee83fce731a3e7acc74
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- Source null
- issn print
- 0732-183X
- issue
- 4
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 661-70
- volume
- 11
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 8478661
- provenance
- batch id
- 6de860041cedd40f623b
- provider
- NCBI PubMed ESummary
- record sha256
- d66ec0604969dd7e10944be0452f6d103a2f59ab578c1bab971254574ef9213e
- response sha256
- f46103bbddb69bd5f2ea5fd2e8d9cab75a19eeb01ce2a0d1f98b4d456a872039
- retrieved at
- 2026-09-09T23:45:23.163950+00:00
- publication date
- display
- 1993 Apr
- precision
- month
- year
- 1993
- publication types
- Clinical Trial
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- source url
- https://pubmed.ncbi.nlm.nih.gov/8478661/
- title
- Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
Preserved source evidence · Not medical advice